REG-PanGenomic Health Inc: Subsidiary Update and Repricing of Outstanding Warrants

Pangenomic HealthAnnouncement

24/04/2023 07:15

24 April 2022

PanGenomic Health Inc.

(“PanGenomic” or the “Company”)

PanGenomic Health Subsidiary Signs Master Services Agreement with Psy
Integrated and Announces Repricing of Outstanding Warrants

Vancouver, British Columbia, Canada, April 24, 2023 – PanGenomic Health Inc.
("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), is pleased to
announce that, further to the announcement made on January 26, 2023, its
subsidiary, MUJN Diagnostics Inc. (“MUJN Diagnostics”), has signed a
definitive master services agreement ("MSA") with Psy Integrated Health, Inc.
(“Psyi”), a management services organisation.

MUJN Diagnostics’ brain health prognostic system tracks the impact of
integrative medicine treatments on patient biomarkers and correlates them with
other symptomatic data. Under the initial statement of work in the MSA, the
trial biomarker testing program will collect patient biomarker data to assist
practitioners and therapists in optimising treatment plans that are
personalised and specific based on the objective data obtained.  MUJN
Diagnostics will pay Psyi a total fee of $45,000 during the initial statement
of work project, which is estimated to be completed by September 2023. 
Either party may terminate the MSA on 30 days prior written notice.

“We are very excited to initiate the collaboration between MUJN and Psyi and
look forward to improving health outcomes for patients suffering from anxiety,
depression and other brain health concerns”, said Vincent Lum, CEO of MUJN
Diagnostics and Co-Founder of PanGenomic Health. “MUJN Diagnostics believe
that alternative therapies for a variety of brain disorders have great promise
and the need for objective data for clinicians and their patients to track the
efficacy of their treatment is a vital component to improve patient health.”

Patrick Callas, Director of Integrated Health for Psyi, added: “We are
excited to be working with MUJN Diagnostics on a new generation of health
diagnostics. Our combined expertise in leading edge alternative healthcare
therapies and disease specific biomarker treatment monitoring is expected to
provide health care professionals in the field of integrative medicine with
tools to improve patient outcomes.”

The Company also announced that its board of directors has approved a
reduction of the exercise price of an aggregate of outstanding 45,472,751
share purchase warrants of the Company (the “Warrants”) from $0.30 per
Class A Common Share of the Company (a “Share”) to $0.20 per Share.

The Warrants to be repriced consist of 20,743,417 outstanding Warrants issued
pursuant to private placements and debt settlements completed by the Company
on 22 April 2021, 16 September 2021, 28 June 2022, 23 December 2022 and 19
January 2023; and 18,000,000 outstanding Warrants issued in connection with
the acquisition of Mindleap Health Inc. on December 9, 2022.  In accordance
with the requirements of the Canadian Securities Exchange (“CSE”), the
repricing of an additional 6,729,334 outstanding Warrants issued in a private
placement completed by the Company on 23 July 2021 will be subject to the
consent of certain holders of those Warrants.  If the required consents are
not provided, the exercise price of these Warrants will remain at $0.30 per
Share.

In accordance with the requirements of the CSE, the exercise price of any
warrants issued as compensation warrants or as finder warrants are not
eligible for repricing.  The expiration date of the Warrants is not being
amended.

Related persons to the Company hold less than 10% of the outstanding Warrants
to be repriced as described above.  The repricing of the Warrants is exempt
from the valuation and minority shareholder approval requirements of
Multilateral Instrument 61-101 Protection of Minority Security Holders in
Special Transactions as the fair market value of the amendments does not
exceed 25% of the Company’s capitalisation.

About Psy Integrated Health

Psy Integrated Health, Inc., with its flagship wellness centre Empower Health
located in the heart of Vancouver, BC. Canada, is a clinic management services
BC benefit company created to accelerate the development of psychedelic
assisted therapeutic treatments and integrated health. Psyi provides
innovative treatment modalities for clients with a variety of indications.
More information can be found at www.psyintegrated.com and
www.empowerhealth.ca.

About MUJN Diagnostics

MUJN Diagnostics Inc. is a wholly-owned subsidiary of PanGenomic Health Inc.
and is focused on developing a decision support system for alternative
healthcare providers. MUJN's Decision Support System includes biomarker
diagnostics, symptom and treatment tracking, and personalised health
analytics, with the goal of empowering healthcare providers and their patients
towards better outcomes.

About PanGenomic Health

PanGenomic Health is a precision health company that has developed a self-care
digital platform to deliver personalised, evidence-based information about
natural treatments. The Company’s initial focus is to support mental health.
Registered as a British Columbia benefit company, PanGenomic Health's mission
is to promote and improve the health and wellness of people and society by
providing a technology platform that identifies plant-based solutions tailored
to the health profile of each individual.

The Directors of PanGenomic take responsibility for this announcement.

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.

For more information, please contact:

Jerry Lai, Investor
Relations                                      
Maryam Marissen, President & CEO

PanGenomic Health
Inc.                                           
PanGenomic Health Inc.

778 743
4642                                                             
778 743 4642

ir@pangenomic.com                                                 
info@pangenomic.com

Patrick Callas, ND

Psy Integrated Health Inc.

604 336 2844

management@psyintegrated.com

Novum Securities Limited, AQSE corporate Advisor

David Coffman / George Duxberry

Tel: +44 (0)207 399 9400

Yellow Jersey PR
Charles Goodwin / Shiv Thambirajah / Soraya Jackson
Investor Relations, UK
Tel: +44 (0)20 3004 9512

This news release includes certain statements that may be deemed
“forward-looking statements”, including statements respecting the services
to be provided by PanGenomic and the consideration to be paid to PanGenomic.
The use of any of the words “anticipate”, “continue”, “estimate”,
“expect”, “may”, “will”, “would”, “project”, “should”,
“believe” and similar expressions are intended to identify forward looking
statements. Although PanGenomic believes that the expectations and assumptions
on which the forward-looking statements are based are reasonable, undue
reliance should not be placed on the forward-looking statements because
PanGenomic can give no assurance that they will prove to be correct. In
particular, there is no assurance that MUJN Diagnostics and/or Psy Integrated
will be able to complete trial biomarker testing program within the timeframes
expected, or at all. Since forward-looking statements address future events
and conditions, by their very nature they involve inherent risks and
uncertainties. These statements speak only as of the date of this News
Release. Actual results could differ materially from those currently
anticipated due to a number of factors and risks including various risk
factors discussed in PanGenomic’s disclosure documents which can be found
under PanGenomic’s profile on www.sedar.com.



Copyright (c) 2023 PR Newswire Association,LLC. All Rights Reserved